X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, MiNA Therapeutics will utilize its proprietary RNAa algorithm and technology platform to identify and characterise RNAa molecules targeting rare genetic diseases of the central nervous system (CNS).
Lead Product(s): RNAa-based Therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Mina Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 04, 2024
Details:
NS-229 is a potent and selective Janus kinase (JAK) 1 inhibitor. It is being evaluated in phase 2 clinical trials for the treatment of eosinophilic granulomatosis with polyangiitis.
Lead Product(s): NS-229
Therapeutic Area: Rare Diseases and Disorders Product Name: NS-229
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
NS-089/NCNP-02 (brogidirsen) targets a gene mutation that can be treated by exon 44 skipping. It is being evaluated in phase 2 clinical trials for the treatment of Duchenne Muscular Dystrophy.
Lead Product(s): Brogidirsen
Therapeutic Area: Genetic Disease Product Name: NS-089/NCNP-2
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
ELZONRIS® (tagraxofusp), a recombinant protein is the only approved treatment for patients with blastic plasmacytoid dendritic cell neoplasm, and the first and only approved CD123-targeted therapy, in both the United States and Europe.
Lead Product(s): Tagraxofusp
Therapeutic Area: Oncology Product Name: Elzonris
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
NS-018 (ilginatinib), is a highly selective and potent inhibitor of JAK2. It is being investigated for the treatment for myelofibrosis (MF), a rare and incurable blood cancer.
Lead Product(s): Ilginatinib
Therapeutic Area: Oncology Product Name: NS-018
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
NS-089 (brogidirsen) which is a novel phosphorodiamidate morpholino oligomer that consists of a novel sequence design involving connected antisense oligonucleotides, targeting exon 44, to serve as an effective treatment for DMD patients amenable to exon 44 skipping.
Lead Product(s): Brogidirsen
Therapeutic Area: Genetic Disease Product Name: NS-089
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
NS-089/NCNP-02 (brogidirsen) which is a novel phosphorodiamidate morpholino oligomer that consists of a novel sequence design involving connected antisense oligonucleotides, targeting exon 44, to serve as an effective treatment for DMD patients amenable to exon 44 skipping.
Lead Product(s): Brogidirsen
Therapeutic Area: Genetic Disease Product Name: NS-089
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2023
Details:
NS-050/NCNP-03, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 50 skipping therapy. Study assessments will include dystrophin production, muscle strength, mobility and functional exercise capacity.
Lead Product(s): NS-050/NCNP-03
Therapeutic Area: Genetic Disease Product Name: NS-050/NCNP-03
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
DFP-10917 (radgocitabine) is a nucleoside analog delivered as a low-dose continuous infusion for the treatment of relapsed/refractory acute myeloid leukemia.
Lead Product(s): DFP-10917
Therapeutic Area: Oncology Product Name: DFP-10917
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Delta-Fly Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
NS-089/NCNP-02 which is a novel phosphorodiamidate morpholino oligomer that consists of a novel sequence design involving connected antisense oligonucleotides, targeting exon 44, to serve as an effective treatment for DMD patients amenable to exon 44 skipping.
Lead Product(s): NCNP-02
Therapeutic Area: Genetic Disease Product Name: NS-089
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
